- Home
- NIVF vs NCNA Comparison
NIVF vs NCNA Comparison
Compare NIVF & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- NCNA
- Stock Information
- Founded
- NIVF 2011
- NCNA 1997
- Country
- NIVF Hong Kong
- NCNA United Kingdom
- Employees
- NIVF N/A
- NCNA N/A
- Industry
- NIVF
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- NCNA Health Care
- Exchange
- NIVF NYSE
- NCNA Nasdaq
- Market Cap
- NIVF 5.0M
- NCNA 4.5M
- IPO Year
- NIVF N/A
- NCNA 2017
- Fundamental
- Price
- NIVF $0.28
- NCNA $1.08
- Analyst Decision
- NIVF
- NCNA Buy
- Analyst Count
- NIVF 0
- NCNA 2
- Target Price
- NIVF N/A
- NCNA $25.00
- AVG Volume (30 Days)
- NIVF 5.3M
- NCNA 238.0K
- Earning Date
- NIVF 02-16-2025
- NCNA 11-25-2024
- Dividend Yield
- NIVF N/A
- NCNA N/A
- EPS Growth
- NIVF N/A
- NCNA N/A
- EPS
- NIVF N/A
- NCNA N/A
- Revenue
- NIVF $5,679,218.00
- NCNA N/A
- Revenue This Year
- NIVF N/A
- NCNA N/A
- Revenue Next Year
- NIVF N/A
- NCNA N/A
- P/E Ratio
- NIVF N/A
- NCNA N/A
- Revenue Growth
- NIVF N/A
- NCNA N/A
- 52 Week Low
- NIVF $0.24
- NCNA $0.96
- 52 Week High
- NIVF $17.24
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- NIVF 36.38
- NCNA 41.41
- Support Level
- NIVF $0.29
- NCNA $1.05
- Resistance Level
- NIVF $0.38
- NCNA $1.18
- Average True Range (ATR)
- NIVF 0.05
- NCNA 0.10
- MACD
- NIVF -0.01
- NCNA 0.00
- Stochastic Oscillator
- NIVF 1.89
- NCNA 36.93
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.